Raymond James Financial Services Advisors Inc. acquired a new stake in DENTSPLY SIRONA Inc (NASDAQ:XRAY) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 4,782 shares of the medical instruments supplier’s stock, valued at approximately $315,000.
Several other large investors also recently added to or reduced their stakes in XRAY. Twin Tree Management LP increased its stake in DENTSPLY SIRONA by 37.1% during the 4th quarter. Twin Tree Management LP now owns 94,865 shares of the medical instruments supplier’s stock valued at $6,245,000 after purchasing an additional 25,674 shares in the last quarter. Arizona State Retirement System increased its stake in DENTSPLY SIRONA by 3.0% during the 4th quarter. Arizona State Retirement System now owns 103,899 shares of the medical instruments supplier’s stock valued at $6,840,000 after purchasing an additional 3,049 shares in the last quarter. D.A. Davidson & CO. bought a new stake in DENTSPLY SIRONA during the 4th quarter valued at $259,000. Advisory Services Network LLC increased its stake in DENTSPLY SIRONA by 565.4% during the 4th quarter. Advisory Services Network LLC now owns 5,496 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 4,670 shares in the last quarter. Finally, Toronto Dominion Bank increased its stake in DENTSPLY SIRONA by 12.7% during the 4th quarter. Toronto Dominion Bank now owns 102,538 shares of the medical instruments supplier’s stock valued at $6,750,000 after purchasing an additional 11,584 shares in the last quarter. Institutional investors own 96.80% of the company’s stock.
Shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) opened at $55.46 on Tuesday. DENTSPLY SIRONA Inc has a one year low of $52.53 and a one year high of $68.98. The company has a quick ratio of 1.45, a current ratio of 2.10 and a debt-to-equity ratio of 0.24. The stock has a market cap of $12,808.04, a price-to-earnings ratio of -8.06, a PEG ratio of 2.46 and a beta of 1.21.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, March 1st. The medical instruments supplier reported $0.82 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.01. DENTSPLY SIRONA had a negative net margin of 39.39% and a positive return on equity of 8.35%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business posted $0.67 EPS. The business’s revenue was up 9.5% compared to the same quarter last year. research analysts expect that DENTSPLY SIRONA Inc will post 2.75 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Friday, April 13th. Stockholders of record on Thursday, March 29th will be paid a $0.0875 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This represents a $0.35 annualized dividend and a dividend yield of 0.63%. DENTSPLY SIRONA’s payout ratio is -5.09%.
A number of analysts have commented on the stock. HC Wainwright set a $63.00 price target on shares of DENTSPLY SIRONA and gave the company a “hold” rating in a research note on Monday, March 5th. Barclays assumed coverage on shares of DENTSPLY SIRONA in a research note on Thursday, March 8th. They set an “equal weight” rating and a $62.00 price target for the company. Barrington Research restated an “outperform” rating and set a $70.00 price target (down previously from $73.00) on shares of DENTSPLY SIRONA in a research note on Monday, March 5th. JPMorgan Chase & Co. decreased their price target on shares of DENTSPLY SIRONA from $75.00 to $70.00 and set an “overweight” rating for the company in a research note on Monday, March 5th. Finally, Credit Suisse Group decreased their price target on shares of DENTSPLY SIRONA from $73.00 to $69.00 and set an “outperform” rating for the company in a research note on Friday, March 2nd. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have issued a buy rating to the company. DENTSPLY SIRONA presently has a consensus rating of “Hold” and a consensus target price of $67.43.
In related news, Director Eric Brandt sold 6,409 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $68.04, for a total value of $436,068.36. Following the transaction, the director now directly owns 12,073 shares of the company’s stock, valued at approximately $821,446.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.99% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of U.S. & international copyright legislation. The original version of this news story can be viewed at https://www.thestockobserver.com/2018/03/20/raymond-james-financial-services-advisors-inc-takes-315000-position-in-dentsply-sirona-inc-xray.html.
DENTSPLY SIRONA Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.